AI news impact · US stocks

Moderna, Inc. (MRNA) news impact

On 2026-11-13 Wave Radar's AI rated the news on Moderna, Inc. as neutral (impact score +20%).

Moderna raised its 2026 revenue growth forecast to 15%–25% and advanced its Merck-partnered individualized cancer therapy toward a 2027 launch, though 2027 cost concerns limited gains.

Direction
Neutral
Impact score
+20%
Confidence
85%
Headlines read
4
Date
2026-11-13
Open MRNA news in Wave Radar

AI assessment

Upgraded revenue guidance for 2026 and progress in individualized cancer vaccines provide fundamental support, partially offset by 2027 cost projections.

Sector impact

Supports sentiment across oncology and mRNA biotechnology developers while keeping focus on cost containment.

Headlines the AI read

Rating history

One rating per trading day the stock was covered.

More on Moderna, Inc.

MRNA valuation · MRNA gamma exposure

How the rating works

After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.